Standing Up to a Hard-Hitting Secondary

Bluebird Bio has been a bullish idea discussed on Market Chess dating back to late-2014, before the stock took off to nearly quadruple in a matter of months. 

Now that BLUE has become one of the hot biotechs du jour, the real test comes with a $400 million secondary priced last night. Thus far, seen on the first intraday chart, below, the stock appears to be standing up to it rather well. 

Beyond that, seen on the second daily chart, a move back over $182 should set in motion a potential falling channel upside breakout (light blue lines). 

Elsewhere, FB and NFLX are still gunning higher as marquee leaders in the market, while crude oil is inching higher into the inventory report coming up.